Literature DB >> 2031608

Energy content of stools in normal healthy controls and patients with cystic fibrosis.

J L Murphy1, S A Wootton, S A Bond, A A Jackson.   

Abstract

Stool energy losses and the sources of energy within the stool were determined in 20 healthy controls and 20 patients with cystic fibrosis while on their habitual pancreatic enzyme replacement treatment. Stool energy losses were equivalent to 3.5% of gross energy intake in healthy children (range 1.3-5.8%). Despite a comparable gross energy intake, stool energy losses were three times greater in patients with cystic fibrosis than controls averaging 10.6% of gross energy intake (range 4.9-19.7%). Stool lipid could account for only 29% and 41% of the energy within the stool in controls and patients with cystic fibrosis respectively and was poorly related to stool energy. Approximately 30% of the energy within the stool could be attributable to colonic bacteria in both the healthy children and patients with cystic fibrosis. These results suggest that stool energy losses in healthy children are relatively modest but that even when patients with cystic fibrosis are symptomatically well controlled on pancreatic enzyme replacement, raised stool energy losses may continue to contribute towards an energy deficit sufficient to limit growth in cystic fibrosis. As the energy content per gram wet weight remains relatively constant (8 kJ/g), stool energy losses may be estimated from simple measurements of stool wet weight.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2031608      PMCID: PMC1793018          DOI: 10.1136/adc.66.4.495

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  THE ORIGIN OF FAECAL LIPIDS. THE COMPOSITION OF FAECAL FATSIN HUMAN SUBJECTS.

Authors:  S M GOMPERTZ; H G SAMMONS
Journal:  Clin Chim Acta       Date:  1963-07       Impact factor: 3.786

2.  A ballistic bomb calorimeter.

Authors:  D S MILLER; P R PAYNE
Journal:  Br J Nutr       Date:  1959       Impact factor: 3.718

Review 3.  Individual dietary surveys: purposes and methods.

Authors:  J W Marr
Journal:  World Rev Nutr Diet       Date:  1971       Impact factor: 0.575

4.  Calorie conversion factors. An experimental reassessment of the factors used in the calculation of the energy value of human diets.

Authors:  D A Southgate; J V Durnin
Journal:  Br J Nutr       Date:  1970-06       Impact factor: 3.718

5.  Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion.

Authors:  D H Shmerling; J C Forrer; A Prader
Journal:  Pediatrics       Date:  1970-11       Impact factor: 7.124

Review 6.  Constipation, dietary fibre and the control of large bowel function.

Authors:  J H Cummings
Journal:  Postgrad Med J       Date:  1984-11       Impact factor: 2.401

7.  On comparing regression lines with unequal slopes.

Authors:  G O Zerbe; P G Archer; N Banchero; A J Lechner
Journal:  Am J Physiol       Date:  1982-03

8.  The microbial contribution to human faecal mass.

Authors:  A M Stephen; J H Cummings
Journal:  J Med Microbiol       Date:  1980-02       Impact factor: 2.472

9.  Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation.

Authors:  R J Stead; I Skypala; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

10.  Comparison of four pancreatic extracts in cystic fibrosis.

Authors:  D W Beverley; J Kelleher; A MacDonald; J M Littlewood; T Robinson; M P Walters
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

View more
  18 in total

Review 1.  Control of malabsorption in cystic fibrosis.

Authors:  J M Littlewood; S P Wolfe
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

3.  Nutrition and survival in cystic fibrosis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

4.  Gastrointestinal handling of [1-13C]palmitic acid in healthy controls and patients with cystic fibrosis.

Authors:  J L Murphy; A E Jones; M Stolinski; S A Wootton
Journal:  Arch Dis Child       Date:  1997-05       Impact factor: 3.791

5.  Proof of concept for identifying cystic fibrosis from perspiration samples.

Authors:  Zhenpeng Zhou; Daniel Alvarez; Carlos Milla; Richard N Zare
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-18       Impact factor: 11.205

Review 6.  Nutritional management of the infant with cystic fibrosis.

Authors:  M R Green; E Buchanan; L T Weaver
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

7.  Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis.

Authors:  J J Reilly; T J Evans; J Wilkinson; J Y Paton
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

8.  A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis.

Authors:  I M Bowler; S P Wolfe; H M Owens; T A Sheldon; J M Littlewood; M P Walters
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

9.  Monitoring steatorrhoea in cystic fibrosis.

Authors:  M De Curtis; F Santamaria; P Ercolini; G Sica; V Bianco; F Ciccimarra
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

10.  Metabolic handling of 13C labelled tripalmitin in healthy controls and patients with cystic fibrosis.

Authors:  J L Murphy; K M Laiho; A E Jones; S A Wootton
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.